The European Medicines Agency has launched a voluntary pilot that will let medicine developers submit data generated with New Approach Methodologies, or NAMs, and receive tailored regulatory feedback.
NAMs include technologies intended to replace, reduce or refine traditional animal studies by using approaches such as advanced cell systems, organoids, computational models and other non-animal methods.
The pilot does not remove existing regulatory requirements. Its purpose is to let developers and regulators examine real datasets together and determine where newer methods can provide information comparable to, or better than, conventional testing.
Why this matters
Before a new medicine enters human trials, developers typically conduct non-clinical studies to understand toxicity, pharmacology and other biological effects.
Animal studies have historically been central to this process because they provide an integrated biological system. But they also have limitations: animal biology does not always predict human responses, some findings are species-specific, and certain human tissues or disease mechanisms can now be modelled more directly in laboratory systems.
New Approach Methodologies aim to improve that evidence base while reducing reliance on animals where scientifically justified.
What the EMA pilot does
Under the voluntary data submission pilot, developers can provide NAM-generated data to EMA and receive feedback on how regulators view the methods and results.
The important feature is that this happens before a formal marketing-authorisation decision depends on the data.
That creates a controlled way to build regulatory experience with emerging methods, identify evidence gaps and understand what validation is needed before a new approach can support or replace an established test.
Why validation is the hard part
A method can be technologically impressive and still not be suitable for regulatory decision-making.
Regulators need to know whether a test is reproducible, whether different laboratories can obtain comparable results, which biological questions it can answer reliably and where it fails.
For example, a human-cell model might reproduce a specific liver-toxicity mechanism very well but provide little information about immune effects occurring across multiple organs.
The question is therefore not whether NAMs are universally better than animal studies. It is which method is fit for which decision.
What this does not mean
EMA has not announced that animal studies are being abolished.
Nor does participation in the pilot mean a developer's method is automatically accepted for future regulatory submissions.
The pilot is a data-sharing and scientific-feedback mechanism designed to accelerate learning on both sides.
That distinction matters because replacing an established test requires evidence that the alternative is sufficiently reliable for the regulatory question being asked.
Why regulators are interested now
Modern drug development increasingly uses human-derived organoids, microphysiological systems, high-content imaging, computational toxicology and machine learning.
Some of these tools can measure human-specific biology that traditional animal models cannot capture well. At the same time, they create new validation problems because models may be technically complex, laboratory-specific or trained on datasets with hidden biases.
A regulatory pilot provides a route to move from promising research methods toward standardized evidence.
Potential practical impact
If certain NAMs prove robust enough, they could reduce development time, lower costs, improve prediction of human toxicity and reduce animal use.
The largest benefit would come not from replacing every animal study, but from using the most informative method for each biological question.
That may eventually produce a mixed testing strategy in which human-relevant laboratory systems, computational models and a smaller number of targeted animal studies are combined rather than relying on a fixed traditional sequence.
What to watch next
The key outputs will be the types of methods developers submit, the quality issues regulators identify and whether the pilot leads to clearer guidance on where specific NAMs can be accepted.
The long-term test is not how many alternative methods are proposed, but how many become reproducible enough to support real regulatory decisions.
Primary source
- European Medicines Agency. Voluntary data submission pilot to advance innovative alternatives to animal testing. 1 September 2026. https://www.ema.europa.eu/en/news/voluntary-data-submission-pilot-advance-innovative-alternatives-animal-testing